Using AI to improve biopsy guidance for nasopharyngeal cancer detection
Detection and Biopsy Guidance of Nasopharyngeal Carcinoma Based on Artificial Intelligence and Endoscopic Images：a Multi-center Prospective Study
This study is testing a new AI tool to help doctors find and biopsy nasopharyngeal cancer more accurately in patients with throat lesions.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 100 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Chinese Academy of Sciences Government |
| Locations | 5 sites (Fuzhou, Fujian and 4 other locations) |
| Trial ID | NCT05202626 on ClinicalTrials.gov |
What this trial studies
This study aims to develop an artificial intelligence tool that enhances the detection of nasopharyngeal carcinoma during endoscopic examinations. By utilizing deep learning algorithms, the tool will assist clinicians in identifying malignancies and guiding biopsies more accurately. The focus is on patients with nasopharyngeal lesions who require biopsy, addressing the challenges posed by the complex anatomy of the nasopharynx. The study will involve observational data collection to evaluate the effectiveness of the AI tool in real clinical settings.
Who should consider this trial
Good fit: Ideal candidates for this study are patients with nasopharyngeal lesions identified through endoscopy who require a biopsy.
Not a fit: Patients who have already been treated for nasopharyngeal cancer or other related cancers will not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could significantly improve the accuracy of nasopharyngeal carcinoma diagnoses and reduce the chances of missed or delayed diagnoses.
How similar studies have performed: Other studies utilizing AI for diagnostic imaging have shown promising results, indicating potential success for this novel approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * The patient was found to have a nasopharyngeal lesion through the nasopharyngeal endoscopy and the clinicans considered it necessary to perform an biopsy. * Hemilateral lesion with limited size. Exclusion Criteria: * Patients with nasopharyngeal cancer, oropharyngeal cancer, hypopharyngeal cancer, etc. who have already been treated.
Where this trial is running
Fuzhou, Fujian and 4 other locations
- Fujian Provincial Cancer Hospital — Fuzhou, Fujian, China (Recruiting)
- Guangdong Provincial People's Hospital — Guangzhou, Guangdong, China (Recruiting)
- Nanfang Hospital, Southern Medical University — Guangzhou, Guangdong, China (Recruiting)
- Sun Yat-Sen University Cancer Center — Guangzhou, Guangdong, China (Recruiting)
- Hainan Provincial People's Hospital — Haikou, Hainan, China (Recruiting)
Study contacts
- Study coordinator: Di Dong, Ph.D
- Email: di.dong@ia.ac.cn
- Phone: +86 010-82618465
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.